33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (T2DM) with non-alcoholic fatty liver disease (NAFLD).

          Related collections

          Author and article information

          Journal
          Hepatol Res
          Hepatology research : the official journal of the Japan Society of Hepatology
          Wiley
          1386-6346
          1386-6346
          Nov 2013
          : 43
          : 11
          Affiliations
          [1 ] Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan; Department of Health Management Center, Toranomon Hospital, Tokyo, Japan.
          Article
          10.1111/hepr.12077
          23489256
          be8c3fa9-8d21-44cb-9814-e4ffbf76fe8d
          © 2013 The Japan Society of Hepatology.
          History

          non-alcoholic fatty liver disease,sitagliptin,type 2 diabetes mellitus

          Comments

          Comment on this article